reported that they have no relationships relevant to the contents of this paper to disclose. Overall 1-year mortality for the SS $33 PCI-treated cohort was 13.3%, rising to 18.8% at 3 years. This is higher than the mortality rate of SYNTAX PCIrandomized patients, although the ES was 4-fold higher, indicating that theirs was a higher risk cohort. The investigators conclude that ULMCA disease with a high SS ($33) should not be a barrier to PCI with EES, as a high SS was not an independent predictor of mortality. However, ES was independently predictive of mortality. The 1-year mortality rate was 1.6% in those with ES <6 and SS $33 and highest in those with ES >6 and SS $33 at 19.5%.
Those with SS <33 and ES <6 had the lowest mortality at 1 year (0.8%). The ULMCA in-stent restenosis rate 
